Back

The epicardial adipose tissue volume is in patients with type 2 diabetes mellitus associated with a lowered myocardial perfusion reserve

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Diabetes and heart disease Diabetes and the Heart ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Andreas Ohrt Johansen

Herlev Hospital, Herlev (Denmark)

5 More presentations in this session

Presentation thumbnail
Regional distribution of diffuse fibrosis in the basal and mid-ventricular AHA segments in patients with type 2 diabetes
Doctor A. Bojer (Gentofte, DK)
Abstract Slides Video
Presentation thumbnail
Circadian heart rate fluctuations predict 21-year cardiovascular and all-cause mortality in type 2 and type 1 diabetes
Doctor L. Nesti (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Twelve-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus
Doctor K. Katogiannis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Impact of diabetes on vascular endothelial growth factor D and cardiovascular mortality in patients with suspected or known coronary artery disease: the ANOX study
Doctor H. Wada (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Type 2 diabetes individuals have a shorter QRS duration, prolonged QTc interval, flatter T wave, and reduced left ventricular cycle volumes compared to matched controls in the UK Biobank
Ms A. Bertrand (Oxford, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and heart disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Prognostic value of epicardial and pericardial adipose tissue in patients with chronic heart failure
thumbnail
Congress Presentation
Effect of empagliflozin on epicardial adipose tissue volume in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
thumbnail
Congress Presentation
Dapagliflozin reduces epicardial adipose tissue in patients with heart failure with reduced ejection fraction and type 2 diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources